These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 27260335)

  • 1. Venetoclax: First Global Approval.
    Deeks ED
    Drugs; 2016 Jun; 76(9):979-87. PubMed ID: 27260335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
    Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
    Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venetoclax: Targeting BCL2 in Hematological Cancers.
    Scheffold A; Jebaraj BMC; Stilgenbauer S
    Recent Results Cancer Res; 2018; 212():215-242. PubMed ID: 30069633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venetoclax: A new wave in hematooncology.
    Mihalyova J; Jelinek T; Growkova K; Hrdinka M; Simicek M; Hajek R
    Exp Hematol; 2018 May; 61():10-25. PubMed ID: 29477371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
    Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT
    BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutics targeting Bcl-2 in hematological malignancies.
    Ruefli-Brasse A; Reed JC
    Biochem J; 2017 Oct; 474(21):3643-3657. PubMed ID: 29061914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venetoclax for the treatment of patients with chronic lymphocytic leukemia.
    Crombie J; Davids MS
    Future Oncol; 2017 Jun; 13(14):1223-1232. PubMed ID: 28492339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
    Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
    Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venetoclax for the treatment of chronic lymphocytic leukemia.
    Gentile M; Petrungaro A; Uccello G; Vigna E; Recchia AG; Caruso N; Bossio S; De Stefano L; Palummo A; Storino F; Martino M; Morabito F
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1307-1316. PubMed ID: 28972395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Research Progress of Oral BCL-2 Inhibitor Venetoclax in the Treatment of Non-Hodgkin's Lymphoma --Review].
    Guo MQ; Luo XY; Wu HY; Huang YX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1622-1626. PubMed ID: 36208277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.
    Salem AH; Agarwal SK; Dunbar M; Enschede SL; Humerickhouse RA; Wong SL
    J Clin Pharmacol; 2017 Apr; 57(4):484-492. PubMed ID: 27558232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing venetoclax activity in hematological malignancies.
    Satta T; Grant S
    Expert Opin Investig Drugs; 2020 Jul; 29(7):697-708. PubMed ID: 32600066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venetoclax for the treatment of multiple myeloma.
    Vaxman I; Sidiqi MH; Gertz M
    Expert Rev Hematol; 2018 Dec; 11(12):915-920. PubMed ID: 30428277
    [No Abstract]   [Full Text] [Related]  

  • 14. Venetoclax in the treatment of chronic lymphocytic leukemia.
    Korycka-Wolowiec A; Wolowiec D; Kubiak-Mlonka A; Robak T
    Expert Opin Drug Metab Toxicol; 2019 May; 15(5):353-366. PubMed ID: 30969139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A literature review of the patent publications on venetoclax - a selective Bcl-2 inhibitor: discovering the therapeutic potential of a novel chemotherapeutic agent.
    Žigart N; Časar Z
    Expert Opin Ther Pat; 2019 Jul; 29(7):487-496. PubMed ID: 31154862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
    Phillips DC; Xiao Y; Lam LT; Litvinovich E; Roberts-Rapp L; Souers AJ; Leverson JD
    Blood Cancer J; 2015 Nov; 5(11):e368. PubMed ID: 26565405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.
    King AC; Peterson TJ; Horvat TZ; Rodriguez M; Tang LA
    Ann Pharmacother; 2017 May; 51(5):410-416. PubMed ID: 28056525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment.
    Vogler M; Walter HS; Dyer MJS
    Br J Haematol; 2017 Aug; 178(3):364-379. PubMed ID: 28449207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
    Roberts AW; Davids MS; Pagel JM; Kahl BS; Puvvada SD; Gerecitano JF; Kipps TJ; Anderson MA; Brown JR; Gressick L; Wong S; Dunbar M; Zhu M; Desai MB; Cerri E; Heitner Enschede S; Humerickhouse RA; Wierda WG; Seymour JF
    N Engl J Med; 2016 Jan; 374(4):311-22. PubMed ID: 26639348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis.
    Freise KJ; Dunbar M; Jones AK; Hoffman D; Enschede SL; Wong S; Salem AH
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):847-53. PubMed ID: 27586967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.